Clinical Pharmacy and Therapeutics

Learning Objectives

By the end of this page, you should be able to:

• Define clinical pharmacy and distinguish it from dispensing-focused pharmacy practice
• Explain the difference between pharmacokinetics and pharmacodynamics and why both matter for dosing decisions
• Describe the structure and purpose of a SOAP note in documenting a pharmacotherapy assessment
• Explain therapeutic drug monitoring (TDM) and identify which drugs typically require it
• Apply a structured pharmacotherapy workup to a simple patient case
• Identify common pitfalls when translating drug information into an individualized treatment plan

Quick Answer

Clinical pharmacy is the practice of applying pharmacological and therapeutic knowledge directly to individual patient care — assessing whether a patient's drug therapy is appropriate, effective, safe, and convenient, and actively recommending changes when it isn't. Therapeutics is the underlying science of using drugs to treat disease, built on pharmacokinetics (what the body does to a drug: absorption, distribution, metabolism, excretion) and pharmacodynamics (what the drug does to the body: mechanism of action, dose-response). It matters because prescribing a drug is not the same as optimizing therapy — the same dose of the same drug can be perfectly appropriate for one patient and dangerous for another depending on organ function, other medications, and individual response, and the clinical pharmacist is the team member trained to catch that difference.

Clinical Pharmacy vs. Dispensing Pharmacy

Dispensing asks "is this prescription valid and safe to hand over?" Clinical pharmacy asks a broader question: "is this the right therapy for this specific patient, right now?" That means going beyond checking the prescription as written to actively evaluating the full picture — indication, dose appropriateness given organ function, duplication with other therapy, monitoring needs, and whether the treatment goal is actually being met. A clinical pharmacist doesn't wait for a prescription to arrive to raise a concern; they may proactively recommend starting, stopping, or adjusting a drug during a ward round based on new lab data.

Pharmacokinetics and Pharmacodynamics: The Two Halves of Therapeutics

These two concepts are often confused because they sound similar, but they answer opposite questions:

• Pharmacokinetics (PK) — What the body does to the drug. The four classic phases are Absorption, Distribution, Metabolism, and Excretion (ADME). PK determines how much drug reaches the site of action and for how long — this is why a patient with kidney failure needs a lower dose of a renally cleared drug even though the drug's mechanism of action hasn't changed at all.
• Pharmacodynamics (PD) — What the drug does to the body. This covers receptor binding, mechanism of action, and the dose-response relationship — why a beta-blocker slows heart rate, and why doubling the dose doesn't necessarily double the effect once receptors are saturated.

A clinical pharmacist uses PK to answer "how much drug, how often" and PD to answer "is this the right drug for this problem, and is it working." Both are needed simultaneously: a perfectly selected drug (right PD) given at the wrong dose for a patient's renal function (wrong PK) can still cause harm, and vice versa.

Therapeutic Drug Monitoring

Not every drug needs its blood level measured — most have a wide enough margin between an effective dose and a toxic dose that clinical judgment (symptoms, standard dosing) is sufficient. Therapeutic drug monitoring (TDM) becomes necessary specifically for drugs with a narrow therapeutic index, where the effective and toxic concentrations are close together, and where blood levels don't reliably correlate with the given dose because of individual variability in absorption or clearance. Classic examples include vancomycin, aminoglycosides (gentamicin), phenytoin, lithium, and digoxin. TDM involves timing a blood draw appropriately (trough, peak) relative to dosing, interpreting the level against the target therapeutic range, and adjusting the regimen — this is one of the most concrete, quantitative applications of clinical pharmacy.

Structuring a Pharmacotherapy Assessment: SOAP

Clinical pharmacists document their patient assessments using the SOAP format, a structure shared across medicine and nursing that keeps clinical reasoning organized and auditable:

• S — Subjective: What the patient reports (symptoms, concerns, how they feel).
• O — Objective: Measurable data (vital signs, lab values, drug levels, physical exam findings).
• A — Assessment: The pharmacist's interpretation — is the drug therapy working, is there a problem (subtherapeutic, toxic, interacting, non-adherent)?
• P — Plan: The specific recommendation (adjust dose, add monitoring, switch drug, counsel patient) and follow-up.

This structure forces the pharmacist to separate what the patient says from what the data shows, and then explicitly connect that evidence to a concrete recommendation — rather than jumping straight from symptoms to a vague suggestion.

Real-World Example

A 68-year-old patient with atrial fibrillation is on warfarin. This week's INR (international normalized ratio, a PD-relevant lab value reflecting the drug's anticoagulant effect) comes back at 4.8, above the target range of 2–3. Using a SOAP structure: Subjective — patient reports no unusual bleeding but started a course of an antibiotic (ciprofloxacin) five days ago for a UTI. Objective — INR 4.8, no active bleeding on exam. Assessment — ciprofloxacin inhibits the CYP enzyme responsible for warfarin metabolism, raising warfarin levels and INR (a pharmacokinetic interaction) even though the warfarin dose itself hasn't changed. Plan — hold or reduce the next warfarin dose, recheck INR in 2–3 days, counsel the patient on bleeding precautions until levels normalize, and flag the interaction for future prescribing.

Why It Matters

The gap between "a drug that works in a clinical trial average population" and "a drug that works safely for this specific patient" is exactly the gap clinical pharmacy exists to close. Individual variation in kidney function, liver function, genetics, other medications, and adherence means that the same prescription can succeed or fail depending entirely on how well it's individualized — and a clinical pharmacist trained in PK/PD reasoning is often the team member best positioned to catch that mismatch before it causes harm.

---

Key Terms

Term	Definition	Related Concept
Pharmacokinetics (PK)	What the body does to a drug: absorption, distribution, metabolism, excretion (ADME)	Dosing, renal/hepatic adjustment
Pharmacodynamics (PD)	What a drug does to the body: mechanism of action, dose-response	Drug selection, efficacy
Therapeutic drug monitoring (TDM)	Measuring blood drug levels to guide dosing for narrow therapeutic index drugs	Vancomycin, phenytoin, lithium
Narrow therapeutic index	A drug property where the effective dose is close to the toxic dose	TDM
SOAP note	Documentation format: Subjective, Objective, Assessment, Plan	Pharmacotherapy workup
Trough level	Drug concentration measured just before the next dose (lowest point)	TDM timing
Drug-drug interaction	Alteration of a drug's effect caused by another drug, via PK or PD mechanisms	Warfarin-antibiotic interaction
Pharmacogenomics	Study of how genetic variation affects individual drug response	Personalized medicine
Evidence-based medicine	Clinical decision-making that integrates best research evidence with clinical expertise and patient values	Guideline-based therapy
Bioavailability	Fraction of an administered dose that reaches systemic circulation unchanged	Pharmacokinetics

Common Mistakes

Misconception: Pharmacokinetics and pharmacodynamics are interchangeable terms for "how a drug works." Why it's wrong: They describe two different, opposite relationships — PK is what the body does to the drug (ADME), PD is what the drug does to the body (mechanism, effect). Confusing them leads to confusing "why the drug isn't reaching the right concentration" with "why the drug isn't producing the right effect at a given concentration" — two very different problems with different solutions. Correct understanding: Use PK to reason about dose and timing; use PD to reason about drug choice and mechanism. A therapy problem can stem from either, or both, independently.

Misconception: Every drug should ideally have its blood level checked to be "extra safe." Why it's wrong: TDM is only clinically useful for drugs with a narrow therapeutic index where blood levels correlate meaningfully with effect or toxicity and dosing based on symptoms alone is unreliable. Routinely monitoring drugs with a wide therapeutic margin (like most antibiotics) adds cost and patient burden without meaningful safety benefit. Correct understanding: TDM is reserved for specific narrow-therapeutic-index drugs (vancomycin, aminoglycosides, phenytoin, lithium, digoxin, and similar) where the risk-benefit clearly favors monitoring.

Misconception: A SOAP note's "Assessment" section is just a restatement of the objective data. Why it's wrong: Restating data adds no clinical value — the assessment is the pharmacist's interpretation connecting subjective and objective findings into a clinical judgment (e.g., "elevated INR likely due to CYP2C9 inhibition from ciprofloxacin"), which is what justifies the plan. Correct understanding: The Assessment must state a clinical interpretation or diagnosis of the medication-related problem, not just repeat the numbers already listed under Objective.

Comparison and Connections

Feature	Pharmacokinetics	Pharmacodynamics
Core question	What does the body do to the drug?	What does the drug do to the body?
Key variables	Absorption, distribution, metabolism, excretion	Receptor binding, mechanism, dose-response
Clinical use	Deciding dose and dosing interval	Deciding drug choice and expected effect
Affected by	Renal/hepatic function, age, weight, genetics	Receptor sensitivity, disease state, tolerance
Example measurement	Drug blood concentration (trough/peak)	Clinical effect (blood pressure, INR, blood glucose)

Practice Questions

Recall

1. What do the letters in ADME stand for, and which branch of therapeutics do they belong to? Answer guidance: Absorption, Distribution, Metabolism, Excretion — these are the four phases of pharmacokinetics.

2. List two drugs commonly requiring therapeutic drug monitoring and explain why. Answer guidance: Vancomycin and phenytoin (also acceptable: gentamicin, lithium, digoxin) — both have a narrow therapeutic index where the effective dose is close to the toxic dose and blood levels don't reliably track with the administered dose alone.

Understanding

3. Explain why a patient with reduced kidney function may need a lower dose of a drug even though the drug's mechanism of action is unchanged. Answer guidance: Reduced kidney function impairs the excretion phase of pharmacokinetics, causing the drug to accumulate at higher-than-intended concentrations over time even at a standard dose, raising toxicity risk — this is a PK problem, not a change in the drug's PD mechanism.

4. Why is the SOAP format useful for a clinical pharmacist's documentation, compared to a free-text note? Answer guidance: SOAP forces a clear separation between what the patient reports, objective measurable data, the pharmacist's clinical interpretation, and the specific action plan — making the reasoning auditable and easy for other clinicians to follow and act on.

Application

5. A patient on phenytoin for seizures has a trough level reported as significantly above the therapeutic range, and now reports new unsteadiness and blurred vision. Using PK/PD reasoning, what is happening and what should the plan be? Answer guidance: The elevated trough level (PK) explains the toxicity symptoms (PD effect — phenytoin toxicity commonly causes nystagmus, ataxia, and diplopia). The plan should include holding or reducing the dose, rechecking the level after an appropriate interval, and reassessing for any new interacting medication or liver function change that may have reduced phenytoin metabolism.

6. A patient starts a new interacting drug that inhibits the metabolism of their existing narrow therapeutic index medication. Using SOAP structure, briefly outline what each section should contain. Answer guidance: Subjective — patient-reported symptoms of toxicity or none reported. Objective — relevant drug level or lab value, new medication start date. Assessment — likely drug interaction causing elevated levels of the narrow therapeutic index drug via inhibited metabolism. Plan — adjust dose or interval, monitor level, and consider alternative to the interacting drug if feasible.

Analysis

7. Two patients receive the identical dose of the identical drug, but one experiences toxicity and the other has no therapeutic effect. Using PK and PD concepts, propose possible explanations for each outcome. Answer guidance: The toxic patient might have impaired metabolism/excretion (PK) causing drug accumulation, or heightened receptor sensitivity (PD). The non-responsive patient might have faster clearance (PK), poor absorption/bioavailability, or reduced receptor sensitivity/tolerance (PD). This illustrates why individualized dosing, not a single standard dose, is often necessary.

8. Critically evaluate the claim: "If therapeutic drug monitoring shows a level within the target range, the patient's therapy is definitely working." Answer guidance: This is not necessarily true — a level within range confirms adequate drug exposure (PK is appropriate) but doesn't guarantee the desired clinical effect (PD) is achieved, since the target range is a population-average estimate. Clinical response (e.g., seizure control, infection resolution) must still be assessed directly; a "good" level with a poor clinical response should prompt reassessment of the diagnosis, target range appropriateness, or presence of resistance/tolerance.

FAQ

How is clinical pharmacy different from pharmacology as a subject? Pharmacology is the basic science studying how drugs work in general (mechanisms, receptor theory, PK/PD principles) usually in idealized or population-average terms. Clinical pharmacy is the applied practice of using that science to make individualized decisions for a specific patient in a specific clinical situation, including monitoring and adjusting therapy over time.

Why do trough levels matter more than random blood draws for TDM? Trough levels (drawn just before the next dose, at the drug's lowest concentration) are drawn at a standardized, reproducible point in the dosing cycle, making them comparable against established therapeutic ranges. A random draw at an unknown point in the dosing interval can't be reliably interpreted against those same reference ranges.

What is the "assessment" in a SOAP note actually supposed to answer? It should answer: is the current drug therapy working, and if not, why — is it a dosing problem, an interaction, non-adherence, or the wrong drug altogether? This interpretive step is what separates clinical reasoning from simply reporting data.

Do all drug interactions require stopping one of the drugs? No. Some interactions are managed by dose adjustment, timing separation (e.g., spacing an antacid from an antibiotic that needs an acidic environment), or increased monitoring rather than discontinuation. The decision depends on the interaction's severity, whether an alternative exists, and how essential each drug is to the patient's care.

Is pharmacogenomics part of standard clinical pharmacy practice yet? It's an expanding part of practice, particularly for specific drug-gene pairs with strong evidence (like CYP2C19 and clopidogrel, or HLA-B*15:02 and carbamazepine), but it isn't yet universally applied to every prescription due to cost and testing-availability limitations. It represents where individualized, PK/PD-informed prescribing is heading.

Quick Revision

• Clinical pharmacy actively optimizes therapy for the individual patient; dispensing checks that a prescription is valid and safe to hand over
• Pharmacokinetics = what the body does to the drug (ADME); pharmacodynamics = what the drug does to the body (mechanism, dose-response)
• TDM is reserved for narrow therapeutic index drugs: vancomycin, aminoglycosides, phenytoin, lithium, digoxin
• Trough levels are drawn just before the next dose for standardized comparison against therapeutic ranges
• SOAP structures clinical documentation: Subjective, Objective, Assessment, Plan
• The Assessment section must contain interpretation, not just repeated data
• A drug interaction can be PK-based (altered metabolism/absorption) or PD-based (additive/opposing effects)
• A level "in range" confirms exposure, not necessarily clinical success — always check the actual clinical response
• Individual variation in organ function, genetics, and adherence explains why identical doses produce different outcomes
• Pharmacogenomics is expanding individualized dosing for specific well-evidenced drug-gene pairs

Related Topics

Prerequisites: Basic pharmacology; pharmacokinetics and pharmacodynamics fundamentals; Hospital Pharmacy

Related Topics: Pharmaceutical Care; Hospital Pharmacy; Pharmacoeconomics

Next Topics: Pharmaceutical Care; Pharmacy Law and Ethics; Health Policy and Public Health